Find alternative origin lanes for any API. Comparable destinations, alternative origins, and the price + competitiveness trade-offs in one ranked playbook.
Apixaban moves from India into 15 active destinations. India to Canada ($8.3M, HHI 0.32, 11 exporters) is the closest substitute lane for buyers historically sourcing into the US. India to UK and India to Brazil rank next on competitiveness. The same Indian exporter cohort serves all three; switching destination changes the price band but preserves the supplier relationship.
| # | Substitute lane | Lane value | Active exporters | HHI | Recommendation |
|---|---|---|---|---|---|
| 1 | Apixaban · IN → CA | Alt destination | 11 exporters | $8.3M · HHI 0.32 | NAI |
| 2 | Apixaban · IN → GB | Alt destination | 9 exporters | $5.6M · HHI 0.38 | NAI |
| 3 | Apixaban · IN → BR | Alt destination | 14 exporters | $4.2M · HHI 0.36 | VAI |
| 4 | Apixaban · IN → SA | Alt destination | 8 exporters | $2.8M · HHI 0.41 | NAI |
| 5 | Apixaban · IN → PH | Alt destination | 5 exporters | $2.2M · HHI 0.42 | VAI |
| 6 | Apixaban · IN → TH | Alt destination | 7 exporters | $1.8M · HHI 0.39 | VAI |
| 7 | Apixaban · IN → MU | Alt destination | 6 exporters | $1.7M · HHI 0.44 | NAI |
| 8 | Apixaban · IN → MY | Alt destination | 5 exporters | $0.56M · HHI 0.5 | VAI |
The AI agent pulls every destination the current Indian (or origin) supplier cohort already serves, plus alternative origins serving the same destination.
Lane value, exporter count, HHI, median price percentile. Rank composite emphasises competitiveness and shared-supplier coverage.
Citation-anchored brief with the ranked alternatives, comparison chips on price and HHI, and a one-click qualification handoff.
Substituting destination on the same origin keeps the supplier in place. The supplier already knows your spec and process; the regulatory burden is the destination, not the manufacturer.
Every substitute carries HHI and exporter count on the row. Buyers see immediately whether the substitute is competitive or just a different concentration problem.
Alternative lanes often clear at different price percentiles. The playbook shows the median band so a buyer knows the cost implication before they pivot.
Where Indian-origin substitution is exhausted, the playbook surfaces alternative origins (China, EU, US) serving the same destination, with the regulatory overlap chip pre-filled.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Twenty molecules · count of competitive alternative lanes (HHI < 0.50, lane value > $500K) per molecule.
The lane substitution playbook is the continuity lever when a lane breaks. PharmaDB ranks every alternative destination and alternative origin by competitiveness, value, and shared-supplier cohort. The view rests on molecule_country_flow, lane_competitiveness, and company_trade_destinations. Refresh cadence is weekly.
Switching destination preserves the supplier relationship: same plant, same spec, same DMF, same inspection history. The regulatory burden falls on the destination market, which is often a known quantity. Switching supplier requires a full qualification cycle.
When the existing-origin substitutes are exhausted, all carry HHI above 0.50, or the destination is structurally not served from the current origin. The playbook then pivots to alternative origins (China-out, EU-out) serving the same destination.
The playbook flags HHI on every substitute. If all substitutes are concentrated, the molecule carries structural single-origin risk and the sole-source audit and dual-source candidate discovery workflows take over. Lane substitution is the first lever; dual-source is the second.
Yes. The same methodology applies to FDF substitution. Buyers on FDF lanes use the playbook to identify alternative-pack-size or alternative-strength lanes that the same exporter cohort already serves.
Alternative lanes often clear at different median prices. The playbook surfaces median + p25 + p75 per substitute. A buyer with leverage often uses the alternative-lane price band as the anchor in renegotiation on the existing lane.
Weekly. Trade aggregates and lane competitiveness refresh weekly. The playbook recomputes on every refresh; the catalog row carries an as-of timestamp on every result page.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.